Subscribe Now Subscribe Today
Research Article
 

Prevalence of Hepatitis B Infection in Rheumatoid Arthritis Patients



Gholam Hossein Alishiri, Gholam Ali Ghorbani and Salimzadeh Ahmad
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
ABSTRACT

Rheumatoid arthritis is a progressive and destructive inflammatory disease of the joints. They had increased mortality depend to use of immunosuppressive drugs. Hepatitis B virus infection is also a health problem in the world. Iran is moderate prevalence endemic area for Hepatitis B virus and it is come too reduced recently by children vaccination. Aim of this study is determined prevalence and screening of Hepatitis B virus infection in rheumatoid arthritis patients. This study is a descriptive cross-sectional which all patients with rheumatic arthritis recruited to study in Tehran in 2012. Then HbsAg and HbcAb assayed for each subjects. In 268 rheumatoid arthritis patients which (82.2%) were female and the average age is 46±14 years old. HbsAg and HbcAb were positive in 4(1.49%) and 9(3.35%), respectively. Only between duration of rheumatoid arthritis and HbcAb had significant association (p<0.014). The present study highlights Rheumatoid arthritis patients treated with immunosuppressive drugs are at increased risk to reactivation of hepatitis B virus, so screening for Hepatitis B virus infection should be performed prior to immunosuppressive therapy.

Services
Related Articles in ASCI
Similar Articles in this Journal
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

Gholam Hossein Alishiri, Gholam Ali Ghorbani and Salimzadeh Ahmad, 2013. Prevalence of Hepatitis B Infection in Rheumatoid Arthritis Patients. Pakistan Journal of Biological Sciences, 16: 747-750.

DOI: 10.3923/pjbs.2013.747.750

URL: https://scialert.net/abstract/?doi=pjbs.2013.747.750
 
Received: January 09, 2013; Accepted: March 04, 2013; Published: April 04, 2013



INTRODUCTION

Rheumatoid arthritis is refractory and progressive inflammatory disease of the joints that is associated mainly with synival hyperplasia (Mandl et al., 2011). Incidence is common in the fourth and fifth decades of life and it is more common in women (Stanmore et al., 2013). Rheumatology clinical criteria suggest as morning stiffness more than one hour for six weeks, more than three symmetrical joints involvement, rheumatoid nodules and positive rheumatoid factor (Summers et al., 2008).

Rheumatoid arthritis patients compared to healthy people had more other chronic diseases such as osteoporosis, infection, cancer, digestive diseases, allergies, vascular and heart disease, also they had increased mortality depend to used of immunosuppressive drugs (Kim and Kim, 2010).

HBV infection is a health problem in the world and 350 million people were carried this virus (Tan et al., 2012). Iran is moderate prevalence endemic area (Ghorbani et al., 2008) and it is come too reduced recently by children vaccination (Marusawa et al., 2000; Ramalingam et al., 2007).

Diagnosis of HBV infection is based on serologic markers such as HBSAg and HBC antibodies that positive before and approximately one month after the appearance of clinical symptoms (Roux et al., 2006). When HbsAg was negative in widow period only diagnostic viral marker is HBC IgM Ab assay (Ramezani et al., 2010). Some of the remedy whom used in rheumatoid arthritis caused immunodeficiency and caused reactive of latent hepatitis. Rituximab, abatacept as well as anti-TNFa should be used prudently in a patient with hepatitis because increased the risk of reactive hepatitis (Vassilopoulos et al., 2010).

Immune-modulator medications as well as Immunosuppressive drugs for treatment of rheumatoid arthritis may be reactivating the occult hepatitis (Ghrenassia et al., 2012).

Considered to prevalence of hepatitis B virus infection in Iran and on other hand prevalence of rheumatoid arthritis obligate uses of immunosuppressive drugs co morbidity of these two disease may be caused fulminant hepatitis (O’Brien et al., 2007). Therefore, this study was design for evaluation of prevalence of hepatitis B infection in these patients.

MATERIALS AND METHODS

This evaluation is a descriptive cross-sectional study which all patients with rheumatic arthritis were referred to the rheumatology clinic in Baqiyatallah hospital at university of medical sciences of Baqiyatallah in Tehran in 2012.

Two hundred sixty eight rheumatoid arthritis patients recruited to study as census sampling after sign consent. Each persons completed prepared questionnaire form. Then from each subjects five ml blood sample take and centrifuged and separated its serum and refrigerated until ready for laboratory assy. Then HbsAg and HbcAb assayed by ELISA test of Diapro Kit manufactured in Italy country.

Exclusion criteria contain who that has a history of hepatitis, malignancies, uncontrolled diabetes, history of chemotherapy and HIV positive.

The Medical Ethics Committee approved this study and after described of aim for patients, study was done and if serology of hepatitis B virus infection was positive they guidance to treatment. In the end data analyzed by SPSS program 11.5 and statistical analysis was done as frequency test for prevalence, differences between the findings of the quantitative variances used Student-T test and discrepancy between the findings of qualitative testing with Chi-2-square analysis and significant level account as p<0.05.

RESULTS

In this study, 268 rheumatoid arthritis patients were included that (82.2%) were female and the average age is 46±14 (range 12-93) years old. The education level was 63.1% diploma and lesser and 87.7% was married. About 82.8% live in urban. Mean duration was 8.8 years and active rheumatoid arthritis was seen in 160 (59.70%) (Table 1).

Treatment of patients contain steroid in 160 (59.70%), azathioprin 51 (19.2%), methotraxate 203 (75.74%) and biologic drugs in 37 (13.80%).

HbsAg and HbcAb were positive in 4(1.49%) and 9(3.35%), respectively. Only between duration of rheumatoid arthritis and HbcAb had significant association (p<0.014), other data are shown in Table 2.

Table 1: Demographic data of rheumatoid patients

Table 2: Involvement of joints, treatment and hepatitis B virus in RA patients

DISCUSSION

Rheumatoid arthritis is a chronic disease of the joints accompanied by progressive destruction and had more mortalities than normal population especially if they treated by immunosuppressive drugs (Urata et al., 2011).Other chronic disease such as HBV hepatitis accompanied with rheumatoid arthritis can increment their complication and it can reactive after begun of immunosuppressant drugs (Mori, 2011). Mortality and morbidity of RA patients infected with chronic hepatitis has increased, especially when they took immunosuppressive drugs, therefore before beginning of therapy screening of hepatitis B virus indicated (Manzano-Alonso and Castellano-Tortajada, 2011).

Iran is moderate endemic prevalence of HBV and vaccination in children reduced its prevalence recently (Ghorbani et al., 2008) but these two diseases is health problem and may worse each other (Alavian et al., 2010; O’Brien et al., 2007). DNA HBV assay is certainly assayed for occult hepatitis but this test did not do in this study because its cost don’t provided (Tan et al., 2012).

Some authors believed that biologic and non biologic drugs had not any risk so prophylaxis against HBV don’t cost benefit and they counsel assay HBV DNA PCR quantitatively and even viral load is increased treated with antiviral (Ndongo et al., 2011).

HBSAg is the best assay screening for HBV infection but it sometimes is negative and other marker such as HBCAb should be examined (Roche and Samuel, 2011).

Fulminant hepatitis may be occurring in RA patients after immunosuppressant therapy so DNA PCR assay is mandatory for detection of occult hepatitis (Watanabe et al., 2012).Improved hepatitis is also at risk after immunosuppressive therapy especially by biologic drugs in RA (Chung et al., 2009) and sometime required to use of entecavir for prophylaxis (Lan et al., 2011).

In this study prevalence of HBCAb is 3.4% which more than prevalence of HBSAg so screening of HBCAb should be adds to HBSAg for meticulous evaluation of HBV infection in RA patients because isolated HBCAb positive is a risk factor for reactivation of hepatitis B virus (Tanaka and Urata, 2012).

Isolated positive HBCAb can be seen in three conditions that the first is acute infections, second chronic hepatitis which may be progressive and third improved and therefore type 1 and 2 after immunosuppressive therapy are at risk for reactivation and fulminant hepatitis (Lee and Weinblatt, 2001; Ryu et al., 2012).

Patients who had HBCAb positive and treated with immunosuppressive drugs, reactivation of hepatitis may be occurred so evaluation every 6 month for hepatitis had indicated until don’t delayed its prophylaxis (Lan et al., 2011).

In this study HBCAb had significant association with long term of disease. Therefore RA patients with long duration time may be had more occult hepatitis than short duration which screening of HBCAb should be performed for them (Kim et al., 2012).Although, prevalence of HBV infection in RA patients resemble to general population (Tanaka and Urata, 2012) but diminished immunity by old age and immunosuppressive therapy for RA may be increased risk of reactivation of HBV so screening was mandated in old age RA patients(Manzano-Alonso and Castellano-Tortajada, 2011).

Prior to Biologic and no Biologic drugs for RA such as anti TNFα, Methotrexate and abatacept which can be reactive occult hepatitis, screening should be performed to prevent reactivation of HBV infection (Roche and Samuel, 2011).

In here RA was more prevalence in women resemble to other study but no any variant and demographic data had significant association with prevalence of HBV infection (Tamori et al., 2011).

Limitation of this study was little budget for HBV DNA PCR viral load assay that it is more sensitive for detection of occult hepatitis in RA patients.

CONCLUSION

Prevalence of hepatitis B in patients with rheumatoid arthritis is similar to normal population but since these patients treated with immunosuppressive drugs are at risk of reactivation of hepatitis and so screening should be considered for them and if need, they be treated for HBV infection.

ACKNOWLEDGMENT

we thank from Baqiyatallah Research Center for Gastroenterology and Liver Disease for funding of this research.

REFERENCES
1:  Alavian, S.M., N. Zamiri, M.M. Gooya, A. Tehrani, S.T. Heydari and K.B. Lankarani, 2010. Hepatitis B vaccination of adolescents: A report on the national program in Iran. J. Public Health Policy, 31: 478-493.
CrossRef  |  PubMed  |  

2:  Chung, S.J., J.K. Kim, M.C. Park, Y.B. Park and S.K. Lee, 2009. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-α therapy. J. Rheumatol., 36: 2416-2420.
CrossRef  |  PubMed  |  

3:  Ghorbani, G.A., S.M. Alavian and H.R. Ghadimi, 2008. Long term effects of one or two doses of hepatitis B vaccine in adults after five years. Pak. J. Biol. Sci., 11: 660-663.
CrossRef  |  PubMed  |  Direct Link  |  

4:  Ghrenassia, E., A. Mekinian, S. Rouaghe, N. Ganne and O. Fain, 2012. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine, 79: 100-101.
CrossRef  |  PubMed  |  

5:  Kim, D.A. and T.Y. Kim, 2010. Is screening for hepatitis necessary in diagnostic evaluation of rheumatoid arthritis in South Korea? J. Rheumatol., 37: 674-675.
CrossRef  |  PubMed  |  

6:  Kim, P.S., G.Y. Ho, P.E. Prete and D.E. Furst, 2012. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res., 64: 1265-1268.
CrossRef  |  PubMed  |  

7:  Lan, J.L., Y.M. Chen, T.Y. Hsieh, Y.H. Chen, C.W. Hsieh, D.Y. Chen and S.S. Yang, 2011. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor α therapy. Ann. Rheumatic Dis., 70: 1719-1725.
CrossRef  |  

8:  Lee, D.M. and M.E. Weinblatt, 2001. Rheumatoid arthritis. Lancet, 358: 903-911.
CrossRef  |  

9:  Mandl, P., E. Naredo, R.J. Wakefield, P.G. Conaghan and M.A. D'Agostino, 2011. A systematic literature review analysis of ultrasound joint count and scoring systems to assess synovitis in rheumatoid arthritis according to the OMERACT filter. J. Rheumatol., 38: 2055-2062.
CrossRef  |  PubMed  |  

10:  Manzano-Alonso, M.L. and G. Castellano-Tortajada, 2011. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J. Gastroenterol., 17: 1531-1537.
CrossRef  |  PubMed  |  Direct Link  |  

11:  Marusawa, H.,S. Uemoto, M. Hijikata, Y. Ueda, K. Tanaka, K. Shimotohno and T. Chiba, 2000. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology, 31: 488-495.
CrossRef  |  

12:  Mori, S., 2011. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod. Rheumatol., 21: 621-627.
CrossRef  |  

13:  Ndongo, S., A. Pouye, D. Dia, N.M. Mbaye and F.K. Lekpa et al., 2011. Seroprevalence of HBsAgs in patients with rheumatoid arthiritis in a hospital setting in Senegal. Med. Trop., 71: 632-633.
PubMed  |  Direct Link  |  

14:  O'Brien, S.F., M.A. Fearon, Q.L. Yi, W. Fan, V. Scalia, I.R. Muntz and E.C. Vamvakas, 2007. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: The Canadian Blood Services experience. Transfusion, 47: 1809-1815.
Direct Link  |  

15:  Ramalingam, S., T. Leung, H. Cairns, P. Sibley and M. Smith et al., 2007. Transmission of hepatitis B virus (genotype E) in a haemodialysis unit. J. Clin. Virol., 40: 105-109.
CrossRef  |  

16:  Ramezani, A., M. Banifazl, A. Eslamifar and A. Aghakhani, 2010. Serological pattern of anti-HBc alone infers occult hepatitis B virus infection in high-risk individuals in Iran. J. Infect. Dev. Ctries. 4: 658-661.
PubMed  |  

17:  Roche, B. and D. Samuel, 2011. The difficulties of managing severe hepatitis B virus reactivation. Liver Int., 31: 104-110.
CrossRef  |  

18:  Roux, C.H., O. Brocq, V. Breuil, C. Albert and L. Euller-Ziegler, 2006. Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology, 45: 1294-1297.
CrossRef  |  

19:  Ryu, H.H., E.Y. Lee, K. Shin, I.A. Choi and Y.J. Lee et al., 2012. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases. Clin. Rheumatol., 31: 931-936.
CrossRef  |  

20:  Stanmore, E.K., J. Oldham, D.A. Skelton, T. O'Neill, M. Pilling, A.J. Campbell and C. Todd, 2013. Risk factors for falls in adults with rheumatoid arthritis: A prospective study. Arthritis Care Res., (In Press). 10.1002/acr.21987

21:  Summers, G.D., C.M. Deighton, M.J. Rennie and A.H. Booth, 2008. Rheumatoid cachexia: A clinical perspective. Rheumatology, 47: 1124-1131.
CrossRef  |  PubMed  |  

22:  Tamori, A., T. Koike, H. Goto, S. Wakitani and M. Tada et al., 2011. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: Evaluation of both HBsAg-positive and HBsAg-negative cohorts. J. Gastroenterol., 46: 556-564.
CrossRef  |  

23:  Tanaka, E. and Y. Urata, 2012. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatol. Res., 42: 333-339.
CrossRef  |  

24:  Tan, J., J. Zhou, P. Zhao and J. Wei, 2012. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin. Rheumatol., 31: 1169-1175.
CrossRef  |  PubMed  |  

25:  Urata, Y., R. Uesato, D. Tanaka, K. Kowatari, T. Nitobe, Y. Nakamura and S. Motomura, 2011. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod. Rheumatol., 21: 16-23.
CrossRef  |  

26:  Vassilopoulos, D., A. Apostolopoulou, E. Hadziyannis, G.V. Papatheodoridis and S. Manolakopoulos et al., 2010. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann. Rheumatic Dis., 69: 1352-1355.
CrossRef  |  

27:  Watanabe, K., K. Takase, S. Ohno, H. Ideguchi, A. Nozaki and Y. Ishigatsubo, 2012. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod. Rheumatol., 22: 470-473.
CrossRef  |  PubMed  |  

©  2021 Science Alert. All Rights Reserved